Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.

You may also be interested in...



Genta Will Appeal FDA “Not Approvable” Action On Genasense

Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.

Genta Will Appeal FDA “Not Approvable” Action On Genasense

Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.

Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel